Valuation: PAVmed Inc.

Market Cap 32.5M 28.59M 26.56M 24.42M 45.8M 3.15B 46.62M 318M 124M 1.54B 122M 119M 5.33B P/E 2026 *
-1.45x
P/E 2027 * -3.55x
Enterprise Value 32.5M 28.59M 26.56M 24.42M 45.8M 3.15B 46.62M 318M 124M 1.54B 122M 119M 5.33B EV / Sales 2026 *
95.6x
EV / Sales 2027 * 49.8x
Free-Float
55.86%
Yield 2026 *
-
Yield 2027 * -
1 day-3.81%
1 week-24.58%
Current month-23.57%
1 month-2.99%
3 months-50.49%
6 months-50.44%
Current year-31.46%
1 week 4.4
Extreme 4.395
5.85
1 month 4.31
Extreme 4.31
6.65
Current year 3.85
Extreme 3.85
28.44
1 year 3.85
Extreme 3.85
28.44
3 years 3.85
Extreme 3.85
270
5 years 3.85
Extreme 3.85
4,365
10 years 3.85
Extreme 3.85
6,858
Manager TitleAgeSince
Compliance Officer 62 2023-03-31
Chief Executive Officer 60 2014-06-25
Director of Finance/CFO 69 2017-03-20
Director TitleAgeSince
Director/Board Member 60 2014-09-30
Chairman 60 2014-06-25
Director/Board Member 71 2014-12-31
Date Insider Type Main position Quantity % Market Cap.
4/2/26 Free

Chief Technology Officer

70,000 1.0966%
4/2/26 Free

Director

13,930 0.2182%
4/2/26
Hcfp Capital Partners Iii LLC
OtherCompany 0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-3.81%-24.58%-74.48%-97.45% 32.5M
+8.71%+5.36%+22.63%+1.80% 213B
+7.46%-6.10%-2.72%-24.77% 135B
-2.54%-17.48%-33.85%-1.38% 117B
+1.42%-2.33%-59.56%-18.02% 64.78B
-0.65%-4.58%+8.98%-9.45% 48.26B
+1.16%-1.94%-28.10%-32.79% 43.08B
+4.71%+2.67%+16.97%+9.50% 39.47B
+3.13%+1.12%+29.35%+32.45% 37.55B
+3.14%+3.47%+88.18%+3.34% 29.78B
Average +2.00%-5.49%-3.26%-13.68% 72.83B
Weighted average by Cap. +3.97%-4.90%+0.32%-6.15%

Financials

2026 *2027 *
Net sales 340K 299K 278K 255K 479K 32.93M 488K 3.32M 1.3M 16.06M 1.28M 1.25M 55.72M 652K 574K 533K 490K 920K 63.19M 936K 6.38M 2.49M 30.82M 2.45M 2.4M 107M
Net income -20.96M -18.43M -17.12M -15.75M -29.54M -2.03B -30.07M -205M -79.87M -990M -78.69M -76.98M -3.43B -18.18M -15.99M -14.85M -13.66M -25.62M -1.76B -26.08M -178M -69.28M -859M -68.25M -66.77M -2.98B
Net Debt - -
Logo PAVmed Inc.
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
Employees
41
Date Price Change Volume
26-07-23 US$4.540 -3.81% 24,951
26-07-22 US$4.720 -14.80% 19,247
26-07-21 US$5.540 -4.32% 25,095
26-07-20 US$5.790 -2.28% 2,351
26-07-17 US$5.925 -1.58% 6,923
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.540USD
Average target price
36.00USD
Spread / Average Target
+692.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PAVM Stock